What the FDA labels say about taking them together
Spironolactone and valsartan
Valsartan's FDA label of August 5, 2026 names spironolactone in its drug interactions section; spironolactone's label does not name valsartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The valsartan label: “Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase …”
Check it at the source: the spironolactone FDA label on DailyMed (effective November 28, 2025, Pfizer Laboratories Div Pfizer Inc); the valsartan FDA label on DailyMed (effective August 5, 2026, Macleods Pharmaceuticals Limited).
What does the spironolactone label say about valsartan?
Spironolactone's label does not name valsartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Spironolactone label, warnings and precautionsExcessive diuresis may cause symptomatic dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Spironolactone label, drug interactionsIn general, discontinue potassium supplementation in heart failure patients who start ALDACTONE [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ]. Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving ALDACTONE.
Source: FDA drug label (Aldactone), Pfizer Laboratories Div Pfizer Inc, effective November 28, 2025 (SPL set 0fed2822-3a03-4b64-9857-c682fcd462bc), via openFDA; the full label on DailyMed
What does the valsartan label say about spironolactone?
Valsartan label, drug interactionsConcomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.
Source: FDA drug label (Valsartan), Macleods Pharmaceuticals Limited, effective August 5, 2026 (SPL set 251ccff4-bf86-453b-9d1c-e3c1ecfd3a46), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Spironolactone | Valsartan | |
|---|---|---|
| Labeled for | Heart failure, Edema (fluid retention), High blood pressure | High blood pressure, Heart failure |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0426 per tablet 25 mg tablet | $0.0963 per tablet 40 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once